{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mooslechner AA"],"funding":["Austrian Science Fund FWF"],"pagination":["3656"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9688325"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(22)"],"pubmed_abstract":["Rapid progressive glomerulonephritis (GN) often leads to end-stage kidney disease, driving the need for renal replacement therapy and posing a global health burden. Low-dose cytokine-based immunotherapies provide a new strategy to treat GN. IL-15 is a strong candidate for the therapy of immune-mediated kidney disease since it has proven to be tubular-protective before. Therefore, we set out to test the potential of low-dose rIL-15 treatment in a mouse model of nephrotoxic serum nephritis (NTS), mimicking immune complex-driven GN in humans. A single low-dose treatment with rIL-15 ameliorated NTS, reflected by reduced albuminuria, less tissue scarring, fewer myeloid cells in the kidney, and improved tubular epithelial cell survival. In addition, CD8<sup>+</sup> T cells, a primary target of IL-15, showed altered gene expression and function corresponding with less cytotoxicity mediated by rIL-15. With the use of transgenic knock-out mice, antibody depletion, and adoptive cell transfer studies, we here show that the beneficial effects of rIL-15 treatment in NTS depended on CD8<sup>+</sup> T cells, suggesting a pivotal role for them in the underlying mechanism. Our findings add to existing evidence of the association of IL-15 with kidney health and imply a potential for low-dose rIL-15 immunotherapies in GN."],"journal":["Cells"],"pubmed_title":["Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8<sup>+</sup> T Cells."],"pmcid":["PMC9688325"],"funding_grant_id":["DK-MOLIN-FWF W1241"],"pubmed_authors":["Mooslechner AA","Schuller M","Schabhuttl C","Artinger K","Rosenkranz AR","Eller K","Eller P","Kirsch AH"],"additional_accession":[]},"is_claimable":false,"name":"Low-Dose rIL-15 Protects from Nephrotoxic Serum Nephritis via CD8<sup>+</sup> T Cells.","description":"Rapid progressive glomerulonephritis (GN) often leads to end-stage kidney disease, driving the need for renal replacement therapy and posing a global health burden. Low-dose cytokine-based immunotherapies provide a new strategy to treat GN. IL-15 is a strong candidate for the therapy of immune-mediated kidney disease since it has proven to be tubular-protective before. Therefore, we set out to test the potential of low-dose rIL-15 treatment in a mouse model of nephrotoxic serum nephritis (NTS), mimicking immune complex-driven GN in humans. A single low-dose treatment with rIL-15 ameliorated NTS, reflected by reduced albuminuria, less tissue scarring, fewer myeloid cells in the kidney, and improved tubular epithelial cell survival. In addition, CD8<sup>+</sup> T cells, a primary target of IL-15, showed altered gene expression and function corresponding with less cytotoxicity mediated by rIL-15. With the use of transgenic knock-out mice, antibody depletion, and adoptive cell transfer studies, we here show that the beneficial effects of rIL-15 treatment in NTS depended on CD8<sup>+</sup> T cells, suggesting a pivotal role for them in the underlying mechanism. Our findings add to existing evidence of the association of IL-15 with kidney health and imply a potential for low-dose rIL-15 immunotherapies in GN.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T05:19:44.855Z","creation":"2025-04-06T11:25:02.376Z"},"accession":"S-EPMC9688325","cross_references":{"pubmed":["36429085"],"doi":["10.3390/cells11223656"]}}